Core Points - The company is holding a shareholders' meeting on August 28, 2025, to discuss important matters including a proposal to provide guarantees for its wholly-owned subsidiary [1][2][6] - The meeting will combine on-site and online voting, with specific time slots for registration and voting [2][3] - The proposal includes a guarantee of up to RMB 400 million for the bank financing needs of its subsidiary, Heilongjiang Zhenbao Island Pharmaceutical Trade Co., Ltd. [3][5] Meeting Details - The meeting will take place at the company's office in Harbin, with the chairman, Fang Tonghua, presiding over the session [2][3] - Shareholders must register for the meeting and provide identification and proof of shareholding [1][2] - The agenda includes the announcement of the meeting's start, introduction of major shareholders, reading of meeting rules, and voting on the proposed resolutions [2][3] Proposal for Guarantee - The company plans to provide a guarantee for its subsidiary, which has a debt-to-asset ratio exceeding 70% [3][5] - The guarantee will be effective from the approval date until the annual shareholders' meeting in 2025 [3][5] - The subsidiary's financials indicate total assets of approximately RMB 3.22 billion and total liabilities of about RMB 2.49 billion [5]

黑龙江珍宝岛药业股份有限公司 2025 年第二次临时股东会 会 议 资 料 2025.8.28 1 目录 | 2025 | 年第二次临时股东会会议须知 3 | | --- | --- | | 2025 | 年第二次临时股东会会议议程 4 | | 议案 | 1：关于为全资子公司提供担保的议案 6 | 2 2025 年第二次临时股东会会议须知 为维护全体股东的合法权益，确保股东会的正常秩序和议事效率， 根据《公司法》《上市公司股东会规则》《上海证券交易所上市公司 自律监管指引第1号——规范运作》及《公司章程》等相关规定，特 制定本次股东会须知如下： 一、会议按照法律、法规、有关规定和《公司章程》的规定进行， 参会人员应自觉维护会议秩序。 二、股东参加股东会，依法享有发言权、质询权、表决权等权利， 并应认真履行法定义务，不得侵犯其他股东的合法权益。 三、参会股东或股东代表应在2025年8月26日上午9时—11时，下 午14时—16时到黑龙江珍宝岛药业股份有限公司（以下简称"公司"） 或者通过电子邮件等形式办理参会登记。已办理参会登记的股东及股 东代表需携带身份证明、股票账户卡、授权委托书等原件于2025年8 月28 ...

Group 1 - The core point of the announcement is the adjustment of the conversion price for the exchangeable bonds issued by the controlling shareholder, Heilongjiang Chuangda Group, to protect the interests of bondholders [1][2] - The first phase of the exchangeable bonds, named "23 Chuang 01 EB," was issued on April 11, 2023, with a total scale of 910 million yuan and a maturity of three years [1] - The conversion price has been revised from 13.35 yuan per share to 12.35 yuan per share, effective from August 27, 2025, following the approval of the bondholders [2] Group 2 - The adjustment of the conversion price is based on the average closing price of the company's stock over the 20 trading days prior to the board resolution and the closing price on the day before the resolution [2] - The number of shares pledged for the exchangeable bonds will still meet the total required for the conversion after the price adjustment [2] - The company will continue to monitor the progress of the exchangeable bonds and fulfill its ongoing information disclosure obligations [2]

换股价格调整的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：603567 证券简称：珍宝岛 公告编号：临 2025-065 黑龙江珍宝岛药业股份有限公司 关于控股股东非公开发行可交换公司债券 2025 年 8 月 20 日，创达集团针对本次换股价格向下修正事项召开债券持有 人会议，审议通过《关于"23 创 01EB"换股价格向下修正的议案》等议案，同 意本次换股价格拟修正为 12.35 元/股。 根据上述决议，"23 创 01EB"的换股价格将从 13.35 元/股向下修正至 12.35 元/股，调整后的换股价格将于 2025 年 8 月 27 日生效。本次换股价格下修后， 创达集团本期可交债质押专户中预备用于交换的股票数量仍满足第一期可交债 全部换股所需的股票数量。 公司将密切关注本期可交债的进展情况，并根据有关规定履行持续信息披露 义务，敬请广大投资者注意投资风险。 特此公告。 近日，黑龙江珍宝岛药业股份有限公司（以下简称"公司"或"珍宝岛"） 收到控股股东黑龙江创达集团有限公司（以下简称"创达集团 ...

Core Viewpoint - Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. announced an adjustment to the conversion price of its convertible bond "23 Chuang 01 EB" to protect the interests of bondholders [1] Group 1: Bond Details - The convertible bond was issued on April 11, 2023, with a total scale of 910 million yuan and a maturity of 3 years [1] - The conversion price has been revised from 13.35 yuan per share to 12.35 yuan per share, effective from August 27 [1] Group 2: Corporate Actions - The adjustment was approved by the board of directors on August 11, and subsequently agreed upon in a bondholders' meeting on August 20 [1] - The pledged account for the shares still meets the conversion demand after the price adjustment [1]

Core Viewpoint - The major shareholders of Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. plan to reduce their holdings, which may impact the company's stock performance and investor sentiment [1][3]. Shareholder Information - As of the announcement date, Bohu Junze Fanglong Equity Investment Center (Limited Partnership) holds 55,792,905 shares, accounting for 5.93% of the total share capital of the company [2]. - Huzhou Saihan Equity Investment Partnership (Limited Partnership) holds 47,098,180 shares, representing 5.01% of the total share capital [2]. Reduction Plan Details - Bohu Junze Fanglong plans to reduce up to 28,229,895 shares, which is no more than 3% of the total share capital, within three months starting from 15 trading days after the announcement. This includes a maximum of 9,409,965 shares through centralized bidding (1% of total share capital) and 18,819,930 shares through block trading (2% of total share capital) [3]. - Huzhou Saihan intends to reduce up to 9,409,965 shares, which is 1% of the total share capital, through centralized bidding within the same timeframe [3]. Shareholder Background - Both Bohu Junze Fanglong and Huzhou Saihan do not have any concerted actions among them [4]. Compliance and Regulations - The reduction plan complies with relevant laws and regulations, including the Securities Law of the People's Republic of China and the Shanghai Stock Exchange's guidelines [6].

Key Points - The core viewpoint of the articles highlights significant corporate announcements, including investment plans, financial performance, and changes in ownership stakes across various companies in the industry [1][2][3] Company Announcements - Dazhihui has not engaged in businesses related to "stablecoins," "virtual asset trading," or "cross-border payments" [1] - Pengding Holdings plans to invest a total of 8 billion yuan in the Huai'an Industrial Park [1] - Tongyuan Environment has won a bid for the expansion project of the sewage treatment plant in Qimen Economic Development Zone, Anhui [1] - Yunda Co., Ltd. reported a revenue of 4.12 billion yuan from express services in July, reflecting a year-on-year growth of 3.75% [2] - Hanwei Electronics intends to acquire a 56.24% stake in Zhancheng Technology for 157 million yuan [1] - Ruoyucheng plans to repurchase shares worth 100 million to 200 million yuan [1] Financial Performance - Fuyao Glass reported a net profit of 4.805 billion yuan for the first half of the year, marking a year-on-year increase of 37.33% [1][2] - Jibite's net profit increased by 24.5% year-on-year, with a proposed dividend of 66 yuan per 10 shares [2] Shareholding Changes - New Zhisoft's OCIL, AL, and CEL collectively plan to reduce their holdings by no more than 2% of the company's shares [1][2] - Zhenbaodao's Bohzhou Junzefanglong intends to reduce its holdings by no more than 3% [1][2] Other Developments - Kesi Technology's actual controller and director Liu Jiande has been placed under detention and is under investigation [3] - Xiling Information's controlling shareholder and general manager Yue Yamei has also been subjected to detention measures [3]

Core Viewpoint - On August 19, no A-share listed companies disclosed any increase in shareholding, while 12 companies announced share reductions by various stakeholders [1]. Group 1: Companies with Share Reductions - Sanxin Medical: Multiple shareholders plan to reduce their holdings [2]. - Nanjing Port: Some directors and senior management personnel plan to reduce their holdings [2]. - Hongye Futures: Shareholders intend to reduce no more than 1% of the company's shares [2]. - AVIC Optoelectronics: A shareholder plans to reduce no more than 28,000 shares [2]. - Heyuan Biological: Huairui Shengyin and its concerted parties will reduce their holdings to below 5% [2]. - New Zhisoft: Multiple shareholders plan to reduce their holdings [2]. - Lutianhua: Shareholders holding over 5% plan to reduce no more than 1% of the company's shares [2]. - Demai Chemical: Chang Lianrong Investment plans to reduce no more than 14,463,463 shares, accounting for no more than 3% of the company's equity [2]. - Fuxin Technology: Controlling shareholders Liu Fukun and Liu Fulin collectively reduced 1.05% of the company's shares [2]. - Huazheng New Materials: Supervisors and senior management plan to reduce no more than 124,900 shares, with the reduction not yet implemented [2]. - Zhenbaodao: Shareholders plan to reduce no more than 4% of the company's shares [2]. - Hefeng Co.: Two shareholders plan to reduce no more than 2.19% of the company's shares [2]. Group 2: Market Signals - The formation of a MACD golden cross signal indicates a positive trend for certain stocks [2].

证券代码：603567 证券简称：珍宝岛 公告编号：临2025-064 黑龙江珍宝岛药业股份有限公司 5%以上股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 1、截至本公告披露日，亳州郡泽方隆股权投资中心（有限合伙）（以下简称 "亳州郡泽方隆"）持有黑龙江珍宝岛药业股份有限公司（以下简称"公司"）股 份 55,792,905 股，占公司总股本的 5.93%。 2、截至本公告披露日，湖州赛瀚股权投资合伙企业（有限合伙）（以下简称 "湖州赛瀚"）持有公司股份 47,098,180 股，占公司总股本的 5.01%。 减持计划的主要内容： 1、自本公告发布之日起 15 个交易日后的 3 个月内，亳州郡泽方隆拟通过集 中竞价交易或大宗交易方式合计减持不超过 28,229,895 股,即不超过公司总股 本的 3%。其中，以集中竞价方式减持不超过 9,409,965 股，即不超过公司股本 总额的 1%，以大宗交易方式减持不超过 18,819,930 股，即不超过公司股本总额 的 2%。若计划减持期间公司发生送 ...

北京商报讯(记者丁宁)8月19日晚间，珍宝岛（603567）发布公告称，公司股东亳州郡泽方隆股权投资 中心(有限合伙)(以下简称"亳州郡泽方隆")、湖州赛瀚股权投资合伙企业(有限合伙)(以下简称"湖州赛 瀚")拟合计减持不超4%公司股份。 具体来看，自公告发布之日起15个交易日后的3个月内，亳州郡泽方隆拟通过集中竞价交易或大宗交易 方式合计减持不超过2822.99万股，即不超过公司总股本的3%。此外，自公告发布之日起15个交易日后 的3个月内，湖州赛瀚拟通过集中竞价交易减持不超过941万股，即不超过公司总股本的1%。 ...